Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Glen Santangelo maintains a Buy rating on Teva Pharmaceutical Industries (NYSE:TEVA) and raises the price target from $19 to $23.
June 27, 2024 | 3:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies analyst Glen Santangelo maintains a Buy rating on Teva Pharmaceutical Industries and raises the price target from $19 to $23.
The raised price target from $19 to $23 by Jefferies, along with the maintained Buy rating, is likely to positively impact TEVA's stock price in the short term as it reflects increased confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100